Randomised phase 3 study of S-1 versus capecitabine, with bevacizumab optional in both arms, in the first-line treatment of metastatic colorectal cancer (mCRC), the SALTO study of the Dutch Colorectal Cancer Group

被引：1

作者：

Kwakman, J. J. M. ^{[1
]}

Simkens, L. H. J. ^{[2
]}

Van Rooijen, J. M. ^{[3
]}

de Wouw, A. J. Van ^{[4
]}

Loosveld, O. J. L. ^{[5
]}

Creemers, G. J. M. ^{[6
]}

Hendriks, M. P. ^{[7
]}

Los, M. ^{[8
]}

Van Alphen, R. J. ^{[9
]}

Polee, M. B. ^{[10
]}

Muller, E. W. ^{[11
]}

Van der Velden, A. M. T. ^{[12
]}

Van Voorthuizen, T. ^{[13
]}

Koopman, M. ^{[14
]}

Mol, L. ^{[15
]}

Van Werkhoven, E. ^{[16
]}

Punt, C. J. A. ^{[1
]}

机构：

[1] Acad Med Ctr, Med Oncol, Amsterdam, Netherlands

[2] Maxima Med Ctr, Med Oncol, Eindhoven, Netherlands

[3] Martini Hosp, Med Oncol, Groningen, Netherlands

[4] VieCuri Med Ctr, Med Oncol, Venlo, Netherlands

[5] Amphia Hosp, Med Oncol, Breda, Netherlands

[6] Catharina Hosp, Med Oncol, Eindhoven, Netherlands

[7] Med Ctr Alkmaar, Med Oncol, Alkmaar, Netherlands

[8] St Antonius Hosp, Med Oncol, Nieuwegein, Netherlands

[9] TweeSteden Hosp, Med Oncol, Tilburg, Netherlands

[10] Med Ctr Leeuwarden, Med Oncol, Leeuwarden, Netherlands

[11] Slingeland Hosp, Med Oncol, Doetinchem, Netherlands

[12] Tergooi Hosp, Med Oncol, Hilversum, Netherlands

[13] Rijnstate Hosp, Med Oncol, Arnhem, Netherlands

[14] Univ Med Ctr Utrecht, Med Oncol, Utrecht, Netherlands

[15] Netherlands Comprehens Canc Ctr, Dept Data Management, Nijmegen, Netherlands

[16] Netherlands Canc Inst, Dept Biometr, Amsterdam, Netherlands

来源：

EUROPEAN JOURNAL OF CANCER | 2017年 / 72卷

关键词：

D O I：

10.1016/S0959-8049(17)30099-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2BA

引用

页码：S5 / S5

页数：1

共 50 条

[31] PRIME STUDY: A RANDOMISED PHASE 3 STUDY OF PANITUMUMAB WITH FOLFOX4 VERSUS FOLFOX4 ALONE AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (mCRC)
Siena, S.
Douillard, J. Y.
Tabernero, J.
Cassidy, J.
Burkes, R.
Barugel, M. E.
Humblet, Y.
Cunningham, D.
Wolf, M.
Gansert, J.
ANNALS OF ONCOLOGY, 2010, 21 : I13 - I13
[32] A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
Cabebe, Elwyn C.
Fisher, George A.
Sikic, Branimir I.
INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1082 - 1087
[33] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study
Antonuzzo, Lorenzo
Giommoni, Elisa
Pastorelli, Davide
Latiano, Tiziana
Pavese, Ida
Azzarello, Domenico
Aieta, Michele
Pastina, Ilaria
Di Fabio, Francesca
Bertolini, Alessandro
Corsi, Domenico Cristiano
Mogavero, Selene
Angelini, Valentina
Pazzagli, Mario
Di Costanzo, Francesco
WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (23) : 7281 - 7288
[34] Efficacy and safety of bevacizumab in combination with irinotecan and capecitabine in first-line treatment of metastatic colorectal cancer
Jungic, Sasa
Tubic, Biljana
Gajanin, Radoslav
Gojkovic, Zdenka
Rakita, Ivanka
VOJNOSANITETSKI PREGLED, 2017, 74 (03) : 249 - 255
[35] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer:The OBELIX study
Lorenzo Antonuzzo
Elisa Giommoni
Davide Pastorelli
Tiziana Latiano
Ida Pavese
Domenico Azzarello
Michele Aieta
Ilaria Pastina
Francesca Di Fabio
Alessandro Bertolini
Domenico Cristiano Corsi
Selene Mogavero
Valentina Angelini
Mario Pazzagli
Francesco Di Costanzo
World Journal of Gastroenterology, 2015, (23) : 7281 - 7288
[36] A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
Elwyn C. Cabebe
George A. Fisher
Branimir I. Sikic
Investigational New Drugs, 2012, 30 : 1082 - 1087
[37] Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer
P García-Alfonso
A J Muñoz-Martin
S Alvarez-Suarez
Y Jerez-Gilarranz
M Riesco-Martinez
P Khosravi
M Martin
British Journal of Cancer, 2010, 103 : 1524 - 1528
[38] Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer
Garcia-Alfonso, P.
Munoz-Martin, A. J.
Alvarez-Suarez, S.
Jerez-Gilarranz, Y.
Riesco-Martinez, M.
Khosravi, P.
Martin, M.
BRITISH JOURNAL OF CANCER, 2010, 103 (10) : 1524 - 1528
[39] Fruquintinib plus capecitabine versus capecitabine as first-line maintenance treatment of metastatic colorectal cancer (mCRC): Update results from the randomized, controlled, phase Ib/II study
Li, Wenhua
Chang, Jinjia
Wang, Chenchen
Peng, Junjie
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[40] EFFICACY AND SAFETY OF CETUXIMAB, OXALIPLATIN AND CAPECITABINE AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC): RESULTS OF A PHASE II STUDY
Barroso, S.
Sanches, E.
Ferreira, J.
Passos, M.
Sa, A.
Nabico, R.
SottoMayor, C.
Santo, Espirito J.
San-Bento, R.
ANNALS OF ONCOLOGY, 2009, 20 : 65 - 65

← 1 2 3 4 5 →